BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $1,139,964.02 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 31,543 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.14, for a total transaction of $1,139,964.02. Following the sale, the chief executive officer now owns 211,718 shares of the company’s stock, valued at approximately $7,651,488.52. This represents a 12.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Neil Kumar also recently made the following trade(s):

• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The stock was sold at an average price of $36.29, for a total transaction of $11,864,362.28.

BridgeBio Pharma Trading Up 2.3 %

Shares of NASDAQ:BBIO traded up $0.80 during trading on Wednesday, hitting $36.29. 4,162,895 shares of the stock were exchanged, compared to its average volume of 2,811,407. The company has a market cap of $6.86 billion, a PE ratio of -15.06 and a beta of 1.07. The company has a fifty day moving average price of $31.53 and a two-hundred day moving average price of $27.79. BridgeBio Pharma, Inc. has a 12-month low of $21.62 and a 12-month high of $37.81.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Evercore ISI lifted their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. Scotiabank boosted their price objective on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 12th. HC Wainwright restated a “buy” rating and issued a $49.00 target price on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Finally, Bank of America lifted their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $49.08.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC raised its stake in shares of BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after buying an additional 472 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in BridgeBio Pharma during the 4th quarter valued at about $41,000. Sterling Capital Management LLC increased its holdings in BridgeBio Pharma by 554.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock valued at $49,000 after acquiring an additional 1,514 shares in the last quarter. Values First Advisors Inc. acquired a new position in BridgeBio Pharma during the third quarter worth about $57,000. Finally, CWM LLC lifted its holdings in shares of BridgeBio Pharma by 132.9% in the third quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after purchasing an additional 1,964 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.